Related Experiment Video

Updated: Jan 14, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade

Adam J Grippin1, Christiano Marconi2, Sage Copling3

  • 1Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. agrippin@mdanderson.org.

Nature
|October 22, 2025
PubMed

Insights

COVID-19 mRNA vaccines can enhance cancer immunotherapy by boosting immune responses against tumors. This approach shows promise for improving survival outcomes in cancer patients, particularly those with "cold" tumors, when combined with immune checkpoint inhibitors.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Immune checkpoint inhibitors (ICIs) improve cancer survival but require pre-existing immunity.
  • Personalized mRNA cancer vaccines sensitize tumors to ICIs but are complex to manufacture.
  • Existing mRNA vaccine technology offers a potential avenue for immune modulation in cancer.

Purpose of the Study:

  • To investigate if mRNA vaccines targeting SARS-CoV-2 can sensitize tumors to ICIs.
  • To explore the immunological mechanisms behind this sensitization.
  • To evaluate the impact of SARS-CoV-2 mRNA vaccination on clinical outcomes in cancer patients receiving ICIs.

Main Methods:

  • Preclinical cancer models were used to assess the effects of SARS-CoV-2 mRNA vaccines on tumor immunity.
  • Analysis of immune correlates, including type I interferon and PD-L1 expression, in preclinical and human studies.
  • Retrospective analysis of large patient cohorts to correlate SARS-CoV-2 mRNA vaccination timing with ICI treatment outcomes.

Main Results:

  • SARS-CoV-2 mRNA vaccines significantly increased type I interferon, priming CD8+ T cells against tumor antigens in preclinical models.
  • Concomitant ICI treatment was necessary for maximal efficacy, particularly in immunologically 'cold' tumors, leading to increased PD-L1 expression.
  • In humans, SARS-CoV-2 mRNA vaccination correlated with increased type I interferon, myeloid-lymphoid activation, and tumor PD-L1 expression.
  • Patients receiving SARS-CoV-2 mRNA vaccines within 100 days of ICI initiation showed significantly improved overall survival, especially those with 'cold' tumors.

Conclusions:

  • Clinically available mRNA vaccines targeting non-tumor antigens can act as potent immune modulators.
  • These vaccines can sensitize tumors to immune checkpoint inhibitors, offering a novel therapeutic strategy.
  • The findings suggest a potential repurposing of existing mRNA vaccine platforms to enhance cancer immunotherapy efficacy.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.2K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
952
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.4K